1,472 Followers on Owler

Celgene

Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases. Read more

CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

CELGENE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Biogen is one of Celgene's top competitors. Biogen was founded in 1978, and its headquarters is in Cambridge, Massachusetts. Like Celgene, Biogen also works within the Biotechnology sector. Biogen has 248 more employees than Celgene.

AbbVie is Celgene's #2 rival. AbbVie was founded in 2013 in North Chicago, Illinois. AbbVie operates in the Pharmaceuticals industry. AbbVie generates $34.9B more revenue than Celgene.

Novartis is a top competitor of Celgene. Novartis is a Public company that was founded in Basel, Basel-City in 1996. Novartis is in the Pharmaceuticals field. Novartis has 101,148 more employees vs. Celgene.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $15.3B a good estimate for Celgene's revenue?

Celgene Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Impact Biomedicines

Jan 2018

Source »
$1.1B
Impact Biomedicines is a biotechnological company that develops treatments for patients with myeloproliferative neoplasms and other types of cancers.
Juno Therapeutics, Inc.

Jan 2018

Source »
$9B
Juno is a biopharmaceutical company that researches and develops cellular immunotherapies for the treatment of cancer.
Anokion SA

Jan 2017

Source »
$45M
Anokion is a biotech company that develops and commercializes antigen-specific immune tolerance technology for the treatment of autoimmune diseases.
Delinia

Jan 2017

Source »
$300M
Delinia is a biotechnology company that develops novel therapeutics for the treatment of autoimmune and inflammatory diseases.
EngMab AG

Oct 2016

Source »
$600M
EngMab focuses on developing T-cell bispecific antibodies for oncology treatments.

These are all the companies that Celgene has acquired. Celgene has acquired 10 companies and its latest acquisition was Impact Biomedicines in Jan 2018. Impact Biomedicines is a biotechnological company that develops treatments for patients with myeloproliferative neoplasms and other types of cancers.

Celgene Funding History

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jul 1987
--

Since Celgene was founded in 1986, it has participated in 1 round of funding. In total Celgene has raised $0. Celgene's funding round was on Jul 1987 for a total of $0

Celgene Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Cyteir is a biotechnology company that discovers and develops synthetic lethal therapies for the treatment of cancer.
$40.2M
Sep 26, 2019
Series B
-
Anokion is a biotech company that develops and commercializes antigen-specific immune tolerance technology for the treatment of autoimmune diseases.
$40M
Sep 10, 2019
Series B
Jan 01, 2017
Immatics is a biopharmaceutical company that develops and commercializes novel T-cell receptor-based immunotherapies for the treatment of cancer.
$75M
Sep 04, 2019
Equity
-
Oncorus is a biotechnological company that researches, develops and commercializes oncolytic viral therapeutics for the treatment of cancer.
$79.5M
Aug 04, 2019
Series B
Oct 02, 2020
Vividion is a biotechnology company that develops and commercializes small molecule therapeutics for the treatment of cancer.
$82M
Apr 29, 2019
Series B
-

These are all the companies that Celgene has invested in. Celgene has invested 10 companies and its latest investment was Impact Biomedicines in Jan 2018. Impact Biomedicines is a biotechnological company that develops treatments for patients with myeloproliferative neoplasms and other types of cancers.

Celgene News

December 15, 2020Drug Store News

Cipla reaches patent litigation settlement with Celgene on generic Revlimid

Celgene has agreed to provide Cipla with a license to Celgene's patents required to manufacture and s... See more »
December 14, 2020India Infoline

Cipla surges ~5% in early trade after settling litigation with Celgene Corporation

As part of the settlement, the Parties will file Consent Judgments in New Jersey that enjoin Cipla fr... See more »
December 8, 2020BioSpace

Year-End Deadline Has Celgene CVR Investors Holding Their Breath for FDA Approval

Is there still hope for Celgene shareholders who hold the $9 per share Contingent Value Rights ticket... See more »
November 16, 2020Endpoints News

Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again

The CVR ($BMYRT) tied to Bristol Myers Squibb's big Celgene buyout took one more step right to the br... See more »
November 16, 2020MarketScreener

FDA delays decision on Bristol Myers cancer therapy due to COVID-19 travel curbs

(marketscreener.com) Bristol Myers Squibb said on Monday the U.S. health regulator has deferred a dec... See more »
November 6, 2020Pharmaceutical Processing World

Bristol Myers Squibb's Celgene Acquisition fueled Q3 growth

Bristol Myers Squibb (NYSE:BMY) posted third-quarter results ahead of analysts' consensus forecast wh... See more »

Celgene Press Releases

August 26, 2019Business Wire

Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corp... See more »
May 15, 2019Business Wire

Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene to Highlight New and Updated Clinical Data at Upcoming America... See more »
April 5, 2019StreetInsider

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron P... See more »
March 4, 2019PR Newswire Asia

Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation

SAN FRANCISCO, March 4, 2019 /PRNewswire/ -- Adagene, Inc., an innovative antibody discovery and engi... See more »
February 5, 2019PR Newswire

Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis

NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platf... See more »
January 29, 2019GlobalNewswire

New potential treatment for leukemia discovered by OICR scientists draws major industry investment

Toronto, Jan. 29, 2019 (GLOBE NEWSWIRE) -- A first-of-its-kind therapy for leukemia discovered by res... See more »

Social Media

Celgene Headquarters

86 Morris Avenue

Summit, New Jersey07901

908-673-9000

Driving Directions »

Trending Companies

Celgene Summary

ABOUT

Overview

Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases. Celgene was founded in 1986. Celgene's headquarters is located in Summit, New Jersey, USA 07901. It has raised undisclosed amount in 1 round. Th...

Frequently Asked Questions about Celgene

  1. When was Celgene founded?

    Celgene was founded in 1986
  2. How much revenue does Celgene generate?

    Celgene generates $15.3B in revenue
  3. How much funding does Celgene have?

    Celgene has historically raised $0 in funding
  4. Where is Celgene's headquarters?

    Celgene's headquarters is in Summit New Jersey, USA
  1. How many employees does Celgene have?

    Celgene has 8,852 employees
  2. What sector does Celgene operate in?

    Celgene is in Biotechnology, Pharmaceuticals
  3. Who are Celgene's competitors?

    Celgene's top competitors are Biogen, AbbVie, Novartis
  4. Who has Celgene invested in?

    Celgene's has invested in companies such as Cyteir, Anokion, Immatics